mProX™ Human KLRD1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The applications of KLRD1, a gene involved in immune responses, have been studied in various contexts. In the context of COVID-19, the use of Thymosin α1 (Tα1) therapy was found to increase the proportion of CD3+ KLRD1+ NKT and TBX21+ CD8+ NKT cells, which are associated with immune activation and cytotoxicity. Tα1 treatment also stimulated the diversity of T cell receptor (TCR) clones. In the context of SARS-CoV-2 vaccination, KLRD1 gene expression was upregulated in CD8+ MAIT cells, indicating their differentiation and potential role in immune response. In the context of hepatitis B vaccine non-responders, KLRD1 expression was found to be higher in CD3highCD16lowKLRG1high NKT cells derived from non-responders, suggesting their involvement in cytotoxicity. In the context of hepatocellular carcinoma (HCC), downregulated ACAA2 (Acetyl-CoA Acyltransferase 2) promoted HCC progression and was associated with increased expression of KLRD1 in CD8+ T cells. Finally, in the context of immune-related skin cutaneous melanoma, a prognostic model based on KLRD1 and other genes was developed to predict patient outcomes and guide immunotherapy. Overall, KLRD1 has been implicated in immune modulation and response in various disease contexts.